INT281639

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 10
Disease Relevance 3.05
Pain Relevance 1.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Map3k12) plasma membrane (Map3k12) cytoplasm (Map3k12)
Map3k12 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
positron emission tomography 468 99.36 Very High Very High Very High
medulla 270 89.44 High High
Hippocampus 45 89.08 High High
Pain 2 88.52 High High
agonist 54 87.72 High High
Neuropathic pain 9 86.68 High High
amygdala 27 86.36 High High
Multiple sclerosis 18 85.92 High High
Inflammatory stimuli 9 80.08 Quite High
imagery 81 71.08 Quite High
Disease Link Frequency Relevance Heat
Herpes Simplex Encephalitis 369 99.08 Very High Very High Very High
Cold Sores 198 89.76 High High
Pain 2 88.52 High High
Neuropathic Pain 13 86.68 High High
Demyelinating Disease 18 85.92 High High
Disease 54 84.80 Quite High
Neurological Disease 99 83.64 Quite High
INFLAMMATION 36 79.76 Quite High
Neurodegenerative Disease 27 77.64 Quite High
Stress 10 67.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pharmacokinetic-pharmacodynamic (PK-PD) modeling has been recognized as a promising tool for preclinical drug development including rational drug combinations (12, 13).
PK-PD Binding (recognized) of
1) Confidence 0.02 Published 2009 Journal Pharm Res Section Body Doc Link PMC2737110 Disease Relevance 0.33 Pain Relevance 0.45
The specific binding in control rats showed a good correlation with [3H]-PK11195 binding (Fig. 4) as was measured by Kurumaji et al. [25] for all three PET tracers.
PK11195 Binding (binding) of associated with positron emission tomography
2) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.23 Pain Relevance 0.25
In addition, the non-specific binding of [18F]-DPA-714 was found to be lower than the non-specific [11C]-(R)-PK11195 binding.
PK11195 Binding (binding) of
3) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.15 Pain Relevance 0
Indeed, pre-treatment with PK11195 showed that [11C]-DPA-713 has lower non-specific binding than [11C]-(R)-PK11195.
PK11195 Binding (binding) of
4) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.09 Pain Relevance 0.18
The high lipophilicity and high non-specific binding of [11C]-(R)-PK11195 result in a low signal-to-noise ratio, which makes detecting mild neuroinflammation or subtle changes due to treatment difficult.
PK11195 Binding (binding) of
5) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.58 Pain Relevance 0.29
Non-specific binding and specific binding of [11C]-(R)-PK11195, [11C]-DPA-713, and [18F]-DPA-714 are displayed in Table 5.
PK11195 Binding (binding) of
6) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.37 Pain Relevance 0.09
Correlations of specific binding in control rats for [11C]-(R)-PK11195, [11C]-DPA-713, and [18F]-DPA-714 with [3H]-PK11195 binding as determined by Kurumaji et al. [25] were assessed with Pearson’s product moment correlation coefficient (r).
PK11195 Binding (binding) of
7) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.55 Pain Relevance 0.11
Non-specific binding and specific binding of [11C]-(R)-PK11195, [11C]-DPA-713, and [18F]-DPA-714 are displayed in Table 5.
PK11195 Binding (binding) of
8) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.37 Pain Relevance 0.09
Another remarkable finding in this study was that the binding of [18F]-DPA-714 and [11C]-DPA-713 in the adrenals could not be blocked by pre-treatment with PK11195, whereas pre-treatment did block the binding of [11C]-(R)-PK11195.
PK11195 Binding (binding) of
9) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.21 Pain Relevance 0.10
The ex vivo biodistribution showed an increased binding in HSE rats as compared to controls and a decreased binding after pre-treatment with PK11195, for all three PET tracers.
PK11195 Binding (binding) of associated with positron emission tomography and herpes simplex encephalitis
10) Confidence 0.00 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.16 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox